Consortium for Advancing Management and Prevention of Cancer in People with HIV

The mission of the AIDS Malignancy Consortium (AMC) is to investigate through clinical trials new treatment and prevention interventions and study the pathobiology of malignancies and their precursors in people living with human immunodeficiency virus (PLWH) in the United States (U.S.) and internationally. The vision of AMC is to reduce incidence, morbidity, and mortality of cancers occurring in PLWH. Since the AMC was established in 1995 (and as of 11/18/24), it has initiated over 97 interventional clinical trials including 10,787 subjects, resulting in 319 publications and 197 abstracts/presentations, and generated evidence that has transformed practice guidelines in the U.S. and low-middle income countries (LMIC) that have a high HIV burden. AMC has established a network of 39 clinical trial sites (including 29 in the U.S, 6 in sub- Saharan Africa, and 4 in Latin America) that are uniquely qualified to carry out its mission, created a network of translational scientists and their research laboratories that support AMC clinical trials, and developed a Career Enhancement Program (CEP) that has fostered a new generation of AMC leaders. AMC has also actively engaged PLWH and cancer survivors in its scientific planning and community outreach in order to better identify the needs of the community, both within the U.S. and globally, as evidenced by the establishment of a Global Community Advisory Board (CGAB) and inclusion of advocates in strategic and protocol planning. AMC has functioned as a single cooperative group since 2005 under the supervision of the Office of HIV- AIDS Malignancies (OHAM) within the Office of the Director of the National Cancer Institute (NCI). This centralized leadership and accountability has helped create a more cohesive structure and uniform approach to group operations and strategic planning. Although AMC focused initially on small pilot, phase I and II trials, the scope of its activities has broadened to include 3 practice-changing randomized phase III trials, including 2 in KS in collaboration with the AIDS Clinical Trials Group (ACTG), and the landmark ANCHOR trial in the U.S. which demonstrated that treatment of anal high-grade squamous intraepithelial neoplasia (HSIL) reduced the incidence of invasive anal cancer, having a profound impact on clinical practice and future research priorities regarding how to most effectively screen for and treat high-grade anal HSIL. Despite challenges posed by the Covid-19 pandemic during years 14-18 of the current funding period, AMC launched a new generation of trials that built upon its prior work, increased overall accrual, began new initiatives in cancer control, prevention, and survivorship, expanded its collaborations with other NCI-funded networks, expanded its laboratory network and biorepository program, and expanded its career enhancement program. AMC will continue to developing hypothesis-driven pilot, phase I, I-II, and III trials designed to address its mission and vision.